The deal includes a fixed consideration of $175m (£141m), comprised of an upfront payment of $135 (£109m) and a long-term note for $40m (£32m), as well as contingent
The post Mallinckrodt to divest BioVectra for £202m appeared first on Pharmaceutical Business review.
Original Article: Mallinckrodt to divest BioVectra for £202m